diagnosi
earli
stage
infect
viral
pathogen
gener
difficult
patient
typic
present
nonspecif
flu
like
symptom
time
definit
diagnosi
made
use
convent
method
infect
alreadi
advanc
untreat
sever
lethal
stage
thu
substanti
need
rapid
accur
reliabl
safe
diagnost
assay
guid
physician
administ
treatment
option
avail
well
notifi
public
health
offici
outbreak
detect
mani
pathogen
transmit
aerosol
rout
progress
diseas
like
acceler
underscor
need
diagnost
assay
earli
stage
diseas
addit
avail
diagnost
assay
requir
biosafeti
level
bsl
bsl
facil
current
specif
treatment
viral
pathogen
discuss
import
develop
sensit
specif
diagnost
assay
carri
parallel
therapeut
develop
ensur
need
met
concept
present
review
wide
applic
virus
howev
limit
discuss
rift
valley
fever
viru
rvfv
venezuelan
equin
enceph
viru
veev
influenza
virus
pathogen
current
studi
context
nanotrap
particl
rvfv
highli
pathogen
arthropod
born
viru
primarili
transmit
mosquito
particularli
heavi
rainfal
although
infect
wide
rang
vertebr
host
rvfv
primarili
affect
livestock
human
mansuroglu
et
al
human
typic
affect
come
close
contact
infect
bodili
fluid
tissu
transmiss
via
mosquito
bite
well
aerosol
may
also
occur
howev
human
dead
end
host
wilson
paweska
et
al
mortal
rate
depend
anim
speci
age
livestock
mortal
rate
high
mortal
rate
reach
high
newborn
young
abort
rate
high
paweska
et
al
fever
often
observ
short
incub
period
symptom
human
usual
mild
includ
febril
ill
resembl
flu
small
percentag
may
develop
seriou
clinic
manifest
retin
lesion
meningoenceph
hepat
sever
hemorrhag
fever
coma
death
recent
year
increas
mortal
amongst
human
report
could
due
evolv
mechan
virul
mutat
increas
surveil
report
pepin
et
al
due
transmiss
via
aerosol
high
pathogen
list
group
iii
bioterror
potenti
categori
emerg
infecti
diseas
niaid
work
rvfv
requir
biosafeti
level
bsl
contain
laboratori
also
prioriti
pathogen
unit
state
depart
agricultur
usda
due
potenti
impact
livestock
ever
introduc
us
highli
suggest
laboratori
staff
work
rvfv
vaccin
therefor
diagnosi
rvfv
restrict
small
number
laboratori
limit
led
delay
diagnost
associ
viru
isol
identif
techniqu
may
pose
problem
healthcar
author
event
rvfv
epidem
crucial
need
rapid
detect
identif
viru
viru
cross
beyond
tradit
endem
boundari
paweska
et
al
pepin
et
al
mani
time
rvfv
infect
recogn
late
infect
ocular
complic
occur
diagnosi
method
includ
viru
isol
antigen
detect
nucleic
acid
amplif
viru
isol
serum
whole
blood
well
tissu
liver
spleen
brain
howev
viru
isol
techniqu
lengthi
expens
optim
face
potenti
epidem
nucleic
acid
techniqu
revers
transcript
polymeras
chain
reaction
rt
pcr
quantit
real
time
pcr
qrt
pcr
real
time
revers
transcript
loop
mediat
isotherm
amplif
assay
rt
lamp
also
develop
pepin
et
al
howev
test
definit
run
parallel
addit
test
antibodi
detect
techniqu
antibodi
primarili
direct
viral
glycoprotein
nucleoprotein
detect
day
infect
pepin
et
al
method
antibodi
detect
rvfv
includ
hemagglutin
inhibit
complement
fixat
indirect
immunofluoresc
enzym
link
immunosorb
assay
elisa
viru
neutral
assay
pose
health
risk
laboratori
person
restrict
use
outsid
rvfv
endem
area
known
gold
standard
detect
viru
neutral
time
consum
expens
lengthi
requir
day
complet
pepin
et
al
elisa
may
allow
rapid
detect
antibodi
rvfv
techniqu
cumbersom
expens
pose
risk
laboratori
personnel
peel
mabey
sandwich
elisa
antigen
detect
sag
elisa
provid
safer
faster
detect
method
howev
rvfv
viremia
remain
high
short
durat
viral
titer
may
reach
undetect
concentr
earli
late
time
point
postinfect
pepin
et
al
summari
still
multipl
limit
current
avail
rvfv
diagnost
method
could
improv
sampl
prepar
technolog
compat
numer
downstream
assay
increas
sensit
safeti
veev
mosquito
born
ill
caus
sever
enceph
hors
human
well
mammal
bird
veev
subtyp
complex
contain
six
subtyp
mosso
da
pedra
cabass
everglad
mucambo
pixuna
rio
negro
aguilar
veev
divid
epizoot
enzoot
group
five
antigen
variant
ab
f
epizoot
group
ab
c
respons
epidem
wherea
enzoot
group
normal
occur
natur
cycl
sylvat
rodent
marsupi
time
bird
culex
mosquito
usual
pathogen
equin
enzoot
subtyp
normal
caus
mild
symptom
epizoot
subtyp
earli
symptom
occur
within
one
day
infect
includ
fever
depress
abnorm
heart
rate
weak
ataxia
neurolog
symptom
appear
day
death
may
occur
within
hour
neurolog
symptom
perman
symptom
recov
anim
may
remain
enzoot
subtyp
result
seriou
diseas
epizoot
subtyp
seen
fatal
rate
hors
furthermor
fatal
case
report
mammal
includ
human
rabbit
dog
sheep
epidem
human
popul
affect
area
infect
human
normal
develop
mild
system
ill
ill
symptom
typic
resolv
within
week
weaver
et
al
neurolog
diseas
caus
symptomat
adult
weaver
et
al
quiroz
et
al
howev
viru
high
fatal
rate
young
elderli
furthermor
placent
damag
abort
stillbirth
report
pregnant
women
kirsch
et
al
vee
often
misdiagnos
dengu
fever
two
virus
share
mani
symptom
aguilar
et
al
pisano
et
al
veev
typic
diagnos
viru
isol
serolog
test
viru
normal
found
blood
cerebrospin
fluid
throat
swab
also
detect
pancrea
tissu
scherer
et
al
valero
fuenmayor
et
al
veev
also
test
isol
guinea
pig
hamster
mice
embryon
chicken
egg
cell
line
vero
rk
bhk
viremia
level
detect
infect
individu
typic
rang
pfu
aguilar
et
al
detect
method
veev
includ
complement
fixat
hemagglutin
inhibit
viru
neutral
immunofluoresc
assay
elisa
elisa
use
detect
viral
antigen
antigen
determin
found
envelop
glycoprotein
veev
blood
wang
et
al
howev
antibodi
detect
possibl
earli
infect
period
viremia
typic
antibodi
veev
made
day
infect
immunofluoresc
assay
prn
test
nucleic
acid
detect
rt
pcr
use
character
differ
veev
subtyp
navarro
et
al
pisano
et
al
influenza
viru
singl
strand
rna
viru
belong
orthomyxovirida
famili
baigent
mccauley
three
type
influenza
b
c
genom
influenza
b
type
consist
eight
segment
pa
ha
np
na
wherea
type
c
consist
seven
linear
segment
type
b
encod
surfac
glycoprotein
hemagglutinin
ha
neuraminidas
na
protein
separ
rna
segment
wherea
hef
protein
type
c
function
properti
ha
na
combin
labella
merel
type
b
virus
transmit
via
respiratori
rout
viru
bind
via
surfac
glycoprotein
na
ha
sialic
acid
found
linkag
human
epitheli
cell
associ
caus
extens
rang
diseas
includ
lower
respiratori
tract
infect
pneumonia
enceph
influenza
b
limit
human
seal
influenza
c
limit
human
swine
influenza
spread
amongst
varieti
speci
avian
mammal
baigent
mccauley
articl
estim
acut
lower
respiratori
infect
caus
million
death
annual
children
age
year
peel
mabey
pandem
highlight
need
reassess
wide
use
influenza
diagnost
test
abil
detect
viral
antigen
clinic
specimen
within
month
nearli
confirm
case
death
countri
signific
evolutionari
distanc
ha
segment
novel
swine
origin
viru
closest
subtyp
rel
demonstr
lack
surveil
test
swine
popul
year
garten
et
al
current
multipl
rapid
influenza
diagnost
test
ridt
avail
physician
use
bedsid
test
identifi
presenc
influenza
b
viral
nucleoprotein
respiratori
sampl
gener
min
less
ridt
use
screen
tool
provid
yesno
answer
quantit
result
ridt
test
guid
physician
prescript
antivir
drug
also
use
screen
tool
respiratori
outbreak
howev
one
limit
ridt
limit
sensit
rang
anywher
result
high
rate
fals
neg
result
find
conduct
cdc
commerci
avail
ridt
influenza
viru
strain
found
test
abl
detect
virus
highest
concentr
mani
kit
unabl
detect
lower
concentr
viru
furthermor
result
vari
base
viru
type
subtyp
exampl
one
ridt
tailor
influenza
captur
abl
detect
mani
influenza
strain
includ
strain
therefor
import
patient
test
within
h
onset
ill
viru
concentr
peak
peterson
et
al
ridt
influenza
often
use
physician
provid
qualit
diagnost
influenza
definit
diagnosi
must
confirm
rt
pcr
molecular
assay
viral
cultur
viral
cultur
gold
standard
viral
cultur
critic
provid
necessari
inform
comparison
variou
strain
subtyp
one
anoth
vaccin
strain
well
monitor
emerg
strain
mutat
amongst
strain
prevent
cfdca
fda
approv
rt
pcr
base
method
includ
quickvu
ab
directigen
ez
flu
ab
binaxnow
influenza
b
current
avail
ridt
detect
viru
respiratori
specimen
contain
high
level
viru
howev
sensit
level
significantli
low
decreas
significantli
viru
level
decreas
kramarow
pastor
lead
fals
neg
result
furthermor
molecular
method
pcr
quickli
becom
golden
standard
risk
cross
contamin
high
spackman
et
al
collect
studi
indic
need
sampl
prepar
technolog
compat
multipl
assay
type
increas
sensit
allow
viral
propag
nanotrap
particl
customiz
hydrogel
microspher
develop
cere
nanosci
target
analyt
separ
discoveri
applic
particl
demonstr
util
innov
tool
collect
concentr
preserv
dilut
level
low
molecular
weight
peptid
protein
biomolecul
biofluid
sampl
pelton
nanotrap
particl
base
cross
link
n
isopropylacrylamid
nipam
appeal
analyt
sequestr
concentr
devic
due
versatil
reproduc
low
product
cost
pelton
hamidi
et
al
luchini
et
al
patanarut
et
al
dougla
et
al
tamburro
et
al
monom
use
gener
nanotrap
particl
also
good
colloid
stabil
biofluid
therebi
creat
larg
surfac
area
ideal
rapid
complet
captur
target
analyt
complex
aqueou
biolog
matric
luchini
et
al
cross
link
polymer
network
make
nanotrap
particl
highli
hydrat
make
possibl
small
molecul
attain
access
interior
particl
patanarut
et
al
furthermor
thermorespons
natur
nipam
monom
impart
particl
signific
degre
flexibl
poros
respons
chang
ph
temperatur
patanarut
et
al
thermorespons
hydrogel
extens
studi
drug
deliveri
applic
knowledg
attain
studi
appli
toward
engin
nanotrap
particl
analyt
collect
devic
hamidi
et
al
nanotrap
particl
function
varieti
affin
bait
facilit
bind
retent
collect
target
protein
peptid
post
translat
modifi
analyt
lipid
fatti
acid
metabolit
nucleic
acid
pathogen
dougla
et
al
tamburro
et
al
versatil
natur
nanotrap
particl
also
allow
tailor
captur
target
analyt
varieti
complex
biolog
matric
includ
blood
serum
plasma
saliva
nasopharyng
fluid
fig
one
method
function
particl
involv
polymer
nipam
monom
anoth
monom
speci
gener
copolym
hydrogel
possess
chemic
properti
monom
exampl
poli
nipam
p
nipam
particl
incorpor
acryl
acid
aac
moieti
synthes
via
precipit
polymer
creat
neg
charg
thermorespons
nanotrap
particl
particl
demonstr
abil
harvest
concentr
low
molecular
weight
protein
speci
serum
luchini
et
al
anoth
way
function
particl
util
revers
broad
spectrum
protein
bind
abil
reactiv
dye
commonli
use
ligand
affin
chromatographi
applic
reactiv
dye
coval
immobil
onto
polym
matrix
low
cost
wide
commerci
avail
make
appeal
affin
bait
nanotrap
particl
nanotrap
particl
also
encapsul
within
cross
link
p
nipam
shell
increas
siev
function
core
particl
architectur
cross
link
outer
shell
particl
either
inert
contain
chemic
moieti
vinyl
sulfon
acid
vsa
demonstr
abil
activ
exclud
interf
albumin
peptid
size
simultan
exclud
larg
unwant
abund
molecul
immunoglobulin
tamburro
et
al
fig
invers
effect
also
achiev
vari
degre
cross
link
particl
nanotrap
particl
high
degre
cross
link
compact
decreas
thermorespons
particl
low
amount
cross
link
exhibit
greater
degre
volum
phase
transit
respons
chang
temperatur
elimin
cross
linker
aspect
particl
architectur
also
tailor
particl
captur
larger
analyt
like
viru
particl
exampl
interpenetr
polym
network
ipn
includ
particl
microspher
structur
introduc
environment
respons
linear
branch
polym
chain
particl
park
choi
anoth
method
synthes
cross
linker
free
shell
structur
around
core
particl
gener
particl
shell
capabl
expand
without
pore
size
limit
effect
cross
linker
gao
frisken
standard
pre
analyt
separ
techniqu
often
requir
mani
day
clean
complex
biofluid
sampl
core
nanotrap
particl
incorpor
affin
bait
capabl
achiev
three
essenti
function
within
minut
captur
dilut
concentr
target
analyt
complex
biofluid
sampl
polym
network
limit
siev
interf
speci
protect
captur
target
analyt
proteolyt
degrad
liotta
et
al
luchini
et
al
longo
et
al
tamburro
et
al
anoth
benefit
afford
use
nanotrap
particl
target
class
analyt
sequest
particl
concentr
smaller
volum
effect
amplifi
fold
sensit
mass
spectrometri
western
blot
immunoassay
high
precis
fredolini
et
al
longo
et
al
tamburro
et
al
grow
interest
field
biomark
discoveri
pharmaceut
biotechnolog
industri
biomark
low
abund
low
molecular
weight
molecul
serv
indic
presenc
stage
specif
diseas
physiolog
pharmacolog
process
patanarut
et
al
complex
biolog
matric
excel
sourc
inform
biomark
although
presenc
high
molecular
weight
high
abund
biomolecul
serum
albumin
immunoglobulin
hinder
detect
elus
low
molecular
weight
biomark
complic
matter
method
use
sampl
collect
transport
compromis
integr
collect
sampl
fluctuat
temperatur
lengthi
transport
time
compromis
viabil
target
biomark
sampl
furthermor
presenc
proteas
sampl
degrad
biomark
interest
ultim
lead
fals
neg
diagnosi
ill
current
mass
spectrometri
favor
techniqu
use
candid
biomark
discoveri
due
throughput
sensit
merrel
et
al
patanarut
et
al
despit
advantag
mass
spectrometri
method
requir
small
sampl
size
consist
purifi
target
protein
presenc
larg
high
abund
biomolecul
hinder
mass
spectrometr
detect
biomark
interest
make
necessari
develop
new
innov
tool
clean
collect
sampl
remov
interf
biomolecul
enrich
mixtur
analyt
interest
easili
integr
exist
workflow
prior
studi
demonstr
abil
nanotrap
particl
protect
captur
analyt
proteolyt
degrad
analyt
preserv
abil
nanotrap
core
particl
function
cibacron
blue
test
use
lysozym
kda
model
protein
trypsin
kda
proteolyt
enzym
patanarut
et
al
trypsin
small
enough
sequest
nanotrap
particl
enzymat
potenc
degrad
lysozym
retain
captur
particl
patanarut
et
al
similar
studi
nanotrap
hydrogel
particl
consist
nipam
aac
copolym
core
encas
within
inert
cross
link
shell
capabl
protect
platelet
deriv
growth
factor
pdgf
small
biomark
c
kda
size
tryptic
degrad
longo
et
al
previou
research
also
employ
nanotrap
particl
effici
concentr
target
analyt
smaller
volum
amplifi
sensit
detect
mass
spectrometri
immunoassay
luchini
et
al
integr
nanotrap
particl
sampl
process
workflow
low
molecular
weight
biomark
greatli
enrich
larg
interf
biomolecul
remov
sampl
achiev
fold
improv
lower
limit
detect
rang
mass
spectrometri
therebi
permit
discoveri
hundr
candid
biomark
previous
undetect
nanogram
per
ml
picogram
per
ml
rang
fredolini
et
al
tamburro
et
al
addit
set
low
abund
peptid
previous
includ
peptideatla
databas
also
discov
mass
spectrometri
nanotrap
hydrogel
particl
util
sampl
process
workflow
tamburro
et
al
nanotrap
particl
core
shell
architectur
demonstr
abil
protect
highli
labil
protein
interleukin
growth
factor
enzymat
degrad
blood
sweat
urin
well
increas
effect
detect
sensit
improv
precis
multipl
reaction
monitor
mrm
analysi
tamburro
et
al
studi
found
incorpor
vsa
shell
matrix
nanotrap
particl
increas
number
dynam
rang
sequest
analyt
interest
allow
mass
spectrometr
identif
protein
known
exist
picogram
per
ml
rang
tamburro
et
al
test
use
infecti
diseas
diagnost
need
rapid
afford
sensit
allow
time
effect
intervent
treatment
banoo
et
al
ideal
diagnost
test
infecti
diseas
would
util
noninvas
andor
easili
attain
biolog
fluid
finger
stick
blood
nasal
excret
saliva
urin
detect
accuraci
precis
earli
stage
viral
bacteri
diseas
antigen
live
organ
pathogen
nucleic
acid
prior
seroconvers
distinguish
activ
diseas
process
immunolog
memori
prior
exposur
banoo
et
al
yet
despit
recent
technolog
develop
challeng
hinder
analyt
detect
biomark
discoveri
also
complic
discoveri
detect
quantif
pathogen
relat
antigen
biofluid
translat
clinic
benefit
exampl
dilut
concentr
clinic
relev
antigen
may
exist
detect
limit
mass
spectrometri
quantit
pcr
exist
immunoassay
presenc
larg
interf
biomolecul
may
also
mask
isol
detect
elus
antigen
final
target
antigen
also
subject
proteolyt
degrad
sampl
collect
transport
andor
storag
serious
compromis
valid
test
result
build
success
nanotrap
particl
biomark
discoveri
function
hydrogel
particl
consist
core
architectur
gener
part
pioneer
effort
develop
highli
sensit
quantit
assay
direct
pathogen
antigen
host
immun
respons
molecul
biofluid
dougla
et
al
result
previou
research
studi
demonstr
util
nanotrap
particl
infecti
diseas
diagnost
exampl
nanotrap
particl
incorpor
acid
black
dye
capabl
increas
sensit
accuraci
urinari
antigen
test
lyme
diseas
bacteri
diseas
caus
spirochet
borrelia
burgdorferi
dougla
et
al
acid
black
function
nanotrap
particl
sequest
enrich
lyme
diseas
antigen
ml
urin
sampl
fold
achiev
immunoassay
sensit
pg
detect
rang
dougla
et
al
recent
studi
shafagati
et
al
demonstr
nanotrap
particl
capabl
captur
virus
includ
rvfv
veev
human
immunodefici
viru
hiv
first
report
extend
analyt
bind
capabl
nanotrap
particl
live
infecti
virus
plaqu
assay
confirm
intact
infecti
viru
bound
nanotrap
particl
mere
lyse
viru
viral
rna
shafagati
et
al
control
experi
indic
nanotrap
particl
toxic
host
cell
shafagati
et
al
furthermor
concentr
viru
propag
resuspend
nanotrap
bound
sampl
proper
growth
medium
ad
sampl
relev
cell
line
addit
studi
also
demonstr
captur
influenza
influenza
b
human
coronaviru
hcov
adenoviru
dengu
virus
nanotrap
particl
viral
supernat
fig
unpublish
data
shafagati
n
fite
k
patanarut
pinkham
c
baer
lepen
b
kehn
hall
k
amaya
kehn
hall
k
narayanan
seen
fig
nanotrap
particl
test
capabl
captur
hcov
demonstr
greatest
enrich
compar
nanotrap
particl
control
compar
lane
lane
influenza
viru
captur
observ
littl
greatest
captur
observ
adenoviru
captur
observ
four
nanotrap
particl
howev
like
due
low
level
viru
present
start
sampl
see
lane
importantli
capabl
high
level
enrich
adenoviru
compar
lane
result
demonstr
broad
viru
captur
potenti
nanotrap
particl
exact
mechan
particl
interact
unknown
hypothes
viral
glycoprotein
interact
nanotrap
particl
similar
fashion
protein
biomark
propos
interact
nanotrap
particl
fig
case
rvfv
hypothes
glycoprotein
gn
gc
interact
cibracon
blue
affin
bait
within
nanotrap
particl
interest
note
virus
captur
date
rel
small
c
nm
smaller
envelop
rna
virus
except
adenoviru
nonenvelop
doubl
strand
dna
viru
averag
size
nanotrap
particl
use
studi
nm
thu
unclear
whether
virus
enter
insid
core
nanotrap
particl
bind
outsid
nanotrap
particl
preferenti
bind
rvfv
nanotrap
particl
contain
cibracon
blue
bait
observ
suggest
bait
play
least
partial
role
bind
nanotrap
particl
recent
modifi
creat
nanotrap
particl
tailor
whole
viru
captur
modifi
nanotrap
particl
larger
size
encas
within
non
cross
link
shell
function
aac
fig
inclus
non
cross
link
shell
onto
particl
architectur
give
nanotrap
environment
respons
arm
captur
larger
viru
particl
studi
underway
determin
whether
environment
respons
arm
increas
abil
nanotrap
particl
captur
virus
abil
nanotrap
particl
enrich
viru
critic
earli
rvfv
veev
infect
low
concentr
viru
result
fals
neg
result
demonstr
sever
research
rvfv
titer
liver
spleen
rise
h
h
titer
drop
quickli
van
vuren
et
al
similarli
veev
level
peak
h
postinfect
dramat
decreas
becom
virtual
undetect
day
infect
wang
et
al
carrara
et
al
presymptomat
diagnosi
would
extrem
use
outbreak
either
natur
bioterror
relat
hundr
thousand
peopl
andor
livestock
may
need
screen
exposur
nanotrap
particl
capabl
captur
enrich
rvfv
veev
cell
cultur
supernat
serum
shafagati
et
al
demonstr
abil
util
nanotrap
particl
clinic
relev
matric
addit
viral
titer
often
low
later
infect
leav
narrow
window
diagnost
assay
therefor
concentr
whole
viru
provid
nanotrap
particl
would
resolv
much
need
problem
fals
neg
result
observ
earli
late
time
point
infecti
process
due
promiscu
affin
bait
cibracon
blue
like
nanotrap
particl
would
capabl
captur
multipl
pathogen
singl
sampl
extens
bind
abil
particl
enhanc
incorpor
multipl
bait
chemistri
within
core
altern
cocktail
differ
nanotrap
particl
also
use
sampl
process
captur
wide
array
analyt
abil
captur
multipl
pathogen
within
one
sampl
enrich
format
import
infecti
agent
known
time
diagnosi
mani
viral
infect
result
similar
symptom
thu
caus
agent
ill
alway
appar
exampl
respiratori
ill
caus
influenza
viru
rhinoviru
display
similar
symptom
fever
cough
sore
throat
often
misdiagnos
one
anoth
lead
faulti
antivir
treatment
bellei
et
al
similarli
vee
difficult
clinic
distinguish
tropic
viral
diseas
dengu
fever
quiroz
et
al
composit
nanotrap
particl
allow
captur
pathogen
present
sampl
follow
captur
downstream
assay
use
determin
pathogen
present
patient
sampl
also
instanc
co
infect
occur
import
ensur
multipl
pathogen
bind
nanotrap
particl
interfer
diagnosi
pathogen
captur
nanotrap
particl
mock
mix
infect
scenario
hiv
rvfv
spike
serum
nanotrap
particl
still
capabl
captur
enrich
rvfv
shafagati
et
al
indic
nanotrap
particl
use
presenc
multipl
virus
similarli
bacteri
viral
co
infect
observ
respiratori
infect
freymuth
et
al
bellei
et
al
chertow
memoli
nanotrap
particl
would
function
well
patient
sampl
demonstr
abil
captur
enrich
influenza
b
virus
coronavirus
adenovirus
fig
n
shafagati
k
fite
patanarut
c
pinkham
baer
b
lepen
k
kehn
hall
unpublish
data
caus
agent
respiratori
diseas
one
import
uniqu
aspect
nanotrap
particl
abil
preserv
sampl
common
preserv
method
often
depend
cold
chain
storag
case
whole
viru
inactiv
viru
sake
preserv
genom
materi
rna
sampl
easili
degrad
presenc
variou
enzym
make
downstream
analys
difficult
sampl
process
properli
field
condit
may
restrict
abil
preserv
whole
viru
preserv
genom
limit
analysi
viabil
pathogen
earli
studi
us
armi
rvfv
confirm
stabil
serum
long
term
cryogen
storag
neutral
ph
klein
et
al
subsequ
studi
demonstr
blood
serum
could
preserv
virul
rvfv
month
shimshoni
barzilai
unfortun
bypass
cold
chain
success
nobuto
whatman
fta
whatman
filter
paper
spot
spike
blood
store
room
temperatur
preserv
rvfv
genom
whole
viru
naslund
et
al
attempt
preserv
genom
rvfv
veev
mock
field
condit
promis
rna
virus
preserv
commerci
avail
rna
extract
buffer
day
tropic
temperatur
prior
place
cold
chain
cost
viral
inactiv
blow
et
al
concern
pandem
influenza
spur
intens
studi
field
collect
preserv
method
viral
sampl
genom
type
world
health
organ
recommend
long
term
storag
whole
blood
swab
sampl
found
viru
preserv
day
respect
fta
card
inactiv
viru
genom
rna
extract
month
store
room
temperatur
likewis
whatman
cellulos
filter
paper
preserv
viru
day
room
temperatur
abdelwhab
et
al
absolut
ethanol
inactiv
influenza
viru
also
allow
rna
extract
store
month
room
temperatur
krafft
et
al
final
rayon
tip
flock
nylon
swab
preserv
viral
rna
day
fereidouni
et
al
group
demonstr
nanotrap
captur
rvfv
influenza
rna
protect
enzymat
degrad
free
float
rna
complet
degrad
presenc
rnase
shafagati
et
al
n
shafagati
k
fite
patanarut
c
pinkham
baer
b
lepen
k
kehn
hall
unpublish
data
rnase
fairli
small
protein
kda
therefor
expect
enter
nanotrap
particl
work
model
rnase
inactiv
bound
affin
bait
mimic
natur
ligand
incorpor
onto
polym
matrix
serv
indirectli
protect
harvest
viral
rna
degrad
fig
puri
roskoski
abil
protect
rvfv
rna
degrad
observ
rvfv
rna
captur
commerci
avail
bio
gel
htp
hydroxyapatit
chromatographi
bead
shafagati
et
al
suggest
uniqu
featur
nanotrap
particl
virus
subject
degrad
soon
sampl
collect
particularli
problemat
sampl
contain
low
viral
titer
lead
fals
neg
test
nanotrap
particl
capabl
captur
enrich
sampl
also
protect
viru
captur
specif
demonstr
nanotrap
particl
capabl
preserv
viral
infect
compar
sampl
without
nanotrap
particl
ambient
increas
temperatur
day
shafagati
et
al
addit
unpublish
work
shafagati
et
al
demonstr
nanotrap
particl
acryl
acid
bait
preserv
viral
infect
influenza
viru
n
shafagati
k
fite
patanarut
c
pinkham
baer
b
lepen
k
kehn
hall
unpublish
data
captur
influenza
viru
nanotrap
particl
viru
incub
ambient
temperatur
least
h
infecti
viru
still
recov
viral
protect
provid
nanotrap
particl
allow
time
unknown
sampl
taken
patient
clinic
case
field
transfer
laboratori
investig
without
need
util
cold
chain
transport
convers
instanc
inactiv
noninfecti
sampl
prefer
laboratori
spars
work
time
consum
requir
highli
train
individu
recent
demonstr
nanotrap
particl
allow
bind
inactiv
viru
captur
nanotrap
particl
infecti
viru
quickli
inactiv
use
two
simpl
method
heat
addit
np
deterg
inactiv
agent
directli
sampl
interestingli
nanotrap
particl
effici
captur
inactiv
viru
bio
gel
htp
hydroxyapatit
bead
shafagati
et
al
abil
captur
inactiv
sampl
particular
import
collect
infecti
sampl
field
allow
safe
transport
sampl
facil
viral
diagnost
often
achiev
elisa
either
antibodi
pathogen
detect
viral
antigen
elisa
methodolog
offer
advantag
afford
rel
quick
highli
sensit
specif
techniqu
compar
molecular
techniqu
viral
antigen
interest
typic
surfac
protein
nucleoprotein
high
abund
within
host
antigen
may
virion
associ
found
bodili
fluid
independ
virion
releas
infect
cell
cell
death
case
rvfv
nucleoprotein
np
abund
protein
within
virion
ferron
et
al
william
et
al
antigen
commerci
elisa
avail
offer
immun
technolog
corp
bdsl
unfortun
date
none
rvfv
elisa
fda
approv
nucleotid
sequenc
np
gene
highli
conserv
among
differ
isol
antibodi
np
detect
earli
infect
william
et
al
therefor
commonli
use
antigen
captur
elisa
detect
rvfv
last
decad
highli
sensit
specif
elisa
detect
rvfv
np
develop
paweska
et
al
b
b
fafetin
et
al
jansen
van
vuren
et
al
jansen
van
vuren
paweska
pepin
et
al
one
disadvantag
elisa
diagnost
platform
pose
biohazard
risk
due
use
live
viru
open
bench
system
pipet
wash
procedur
use
od
read
furthermor
reagent
expens
cumbersom
intern
antigen
control
readili
avail
well
character
pepin
et
al
paper
publish
paweskaet
al
research
address
least
one
disadvantag
develop
sandwich
antigen
elisa
sag
elisa
work
noninfecti
sampl
paweska
et
al
author
first
inactiv
supernat
rvfv
infect
vero
cell
cultur
h
presenc
tween
demonstr
thermo
inactiv
np
antigen
detect
earli
infect
h
human
patient
infect
rvfv
sag
elisa
sensit
specif
wherea
experiment
infect
sheep
sensit
specif
paweska
et
al
anoth
paper
publish
fukushi
et
al
antigen
captur
elisa
rvfv
np
use
new
monoclon
antibodi
develop
author
test
histidin
tag
recombin
np
rnp
cultur
supernat
infect
rvfv
found
detect
limit
ng
per
rnp
pfu
per
rvfv
rvfv
antigen
cultur
supernat
rvfv
infect
cell
infect
newli
develop
ag
captur
elisa
detect
limit
ten
time
higher
report
detect
rvfv
antigen
detect
limit
still
lower
compar
qrt
pcr
assay
fukushi
et
al
recent
work
group
demonstr
captur
enrich
rvfv
np
viral
supernat
anim
serum
fig
seven
differ
nanotrap
particl
analyz
determin
abil
captur
rvfv
np
panel
effect
np
captur
show
robust
enrich
compar
nt
sampl
compar
lane
interestingli
nanotrap
particl
contain
two
affin
bait
reactiv
red
reactiv
yellow
experi
also
perform
determin
abil
captur
rvfv
np
clinic
relev
matric
rvfv
np
spike
bovin
sheep
goat
donkey
serum
incub
analyz
western
blot
analysi
rvfv
np
detect
four
sera
analyz
incub
fig
contrast
concentr
rvfv
np
lane
detect
western
blot
analysi
result
demonstr
capabl
captur
enrich
rvfv
np
serum
rvfv
np
found
free
serum
well
within
virion
coat
viral
rna
thu
nanotrap
particl
capabl
captur
virion
associ
free
np
provid
method
captur
pool
np
analyz
downstream
assay
includ
sandwich
elisa
describ
theori
target
pool
np
increas
sensit
elisa
goal
compar
qrt
pcr
detect
rvfv
studi
current
underway
addit
shown
nanotrap
particl
capabl
captur
inactiv
rvfv
shafagati
et
al
assay
could
perform
bsl
environ
influenza
diagnost
much
advanc
multipl
assay
type
avail
physician
clinic
diagnost
laboratori
viral
antigen
detect
ridt
avail
later
flow
assay
identifi
presenc
influenza
b
viral
nucleoprotein
respiratori
sampl
gener
min
less
test
success
recogn
infect
high
titer
fals
neg
result
like
occur
low
viral
concentr
therefor
key
diagnost
area
could
benefit
nanotrap
technolog
larger
volum
sampl
enrich
use
nanotrap
particl
provid
accur
detect
interestingli
mani
ridt
influenza
b
card
allow
detect
free
virion
associ
nucleoprotein
lysi
step
prior
appli
swab
materi
strip
current
research
effort
underway
determin
whether
nanotrap
particl
enhanc
sensit
ridt
assay
enrich
viru
low
abund
analyt
prior
test
later
flow
assay
recent
interest
emerg
role
cytokin
potenti
serum
biomark
predict
sever
viral
infect
sever
paper
demonstr
host
respons
increas
earli
infect
prolong
could
actual
worsen
diseas
known
cytokin
storm
paquett
et
al
mous
ferret
anim
model
shown
virul
strain
influenza
viru
associ
increas
level
biomark
il
furthermor
patient
sampl
show
increas
il
level
nasal
lavag
fluid
earli
influenza
infect
davey
et
al
il
import
featur
host
respons
predict
diseas
outcom
found
increas
level
serum
patient
sampl
contain
mani
high
abund
protein
recent
paper
demonstr
il
could
potenti
diseas
sever
biomark
pandem
influenza
paquett
et
al
infect
veev
rvfv
also
result
increas
level
transcript
interferon
interferon
regul
factor
toll
like
receptor
brain
bouloy
et
al
erwin
cohen
et
al
conjunct
high
rvfv
viral
titer
level
serum
cytokin
il
il
g
gsf
significantli
increas
h
postinfect
drastic
drop
normal
cytokin
level
h
postinfect
van
vuren
et
al
cours
viral
infect
viru
antagon
innat
adapt
immun
respons
lead
sever
diseas
bouloy
et
al
recent
demonstr
nanotrap
particl
help
enhanc
detect
il
cell
cultur
supernat
follow
rvfv
infect
narayanan
et
al
detect
earli
host
respons
biomark
promis
avenu
allow
accur
earli
diagnost
prior
sever
symptom
diseas
nanotrap
particl
previous
shown
sequest
low
abund
chemokin
longo
et
al
one
core
issu
collect
cytokin
extrem
short
half
life
roughli
min
degrad
soon
blood
drawn
zhou
et
al
furthermor
cytokin
il
begin
decreas
significantli
h
paquett
et
al
nanotrap
particl
shown
protect
cytokin
degrad
room
temperatur
longo
et
al
anoth
import
class
biomark
cell
surfac
protein
receptor
cytokin
import
indic
diseas
state
clinic
outcom
fac
analysi
common
method
cell
surfac
protein
analysi
requir
least
sever
hundr
thousand
protein
per
cell
measur
signal
unfortun
protein
level
found
low
abund
cytokin
receptor
low
detect
joensson
et
al
nanotrap
particl
work
enrich
cytokin
cell
surfac
protein
serum
nasal
swab
sampl
smaller
sampl
size
simultan
exclud
serum
albumin
immunoglobulin
allow
downstream
analysi
elisa
variou
multiplex
assay
zhou
et
al
enhanc
earli
detect
also
allow
comparison
virul
nonvirul
strain
virus
host
immun
respons
scientist
physician
tri
year
develop
panel
biomark
would
predict
develop
sever
diseas
individu
biomark
candid
reach
level
specif
sensit
need
proper
diagnosi
diseas
petricoin
et
al
determin
number
biomark
allow
proper
treatment
diseas
late
also
provid
extens
detail
host
defens
concept
extens
studi
cancer
research
extend
viral
diagnost
could
especi
import
influenza
detect
sever
diseas
vari
subtyp
viru
studi
conduct
davey
et
al
demonstr
seven
marker
significantli
correl
diseas
progress
serum
influenza
patient
il
il
lbp
il
mcp
ip
davey
et
al
influenza
infect
predispos
individu
secondari
bacteri
infect
caus
streptococcu
pneumonia
streptococcu
aureu
support
evid
influenza
pandem
caus
synergi
influenza
pneumococc
infect
host
respons
diseas
progress
pneumonia
variabl
individu
sever
biomark
inflammatori
mediat
protein
ip
thought
activ
cell
provid
favor
environ
pneumonia
infect
influenza
infect
avoid
progress
pneumonia
stop
biomark
detect
earli
enough
viral
infect
brand
et
al
howev
due
complex
serum
sensit
detect
panel
low
make
accur
diagnosi
due
composit
promiscu
nanotrap
particl
high
abund
protein
exclud
sever
biomark
captur
test
simultan
review
provid
overview
broad
util
nanotrap
particl
technolog
platform
biospecimen
sampl
storag
initi
work
present
lay
foundat
next
stage
research
develop
effort
aim
end
goal
provid
solut
improv
earli
detect
identif
pathogen
strain
monitor
diseas
progress
treatment
efficaci
futur
direct
focus
three
main
area
biospecimen
collect
storag
analyt
enrich
multiplex
assay
develop
initi
result
indic
abil
preserv
multipl
class
analyt
even
increas
temperatur
investig
fundament
mechan
protect
provid
valuabl
insight
process
potenti
extend
abil
prevent
degrad
valuabl
sampl
reagent
store
ambient
condit
without
cold
chain
storag
also
plan
develop
new
process
option
inactiv
pathogen
biospecimen
prior
transport
storag
abil
captur
multipl
class
analyt
singl
complex
biofluid
environment
sampl
use
combin
nanotrap
particl
architectur
provid
simpl
reliabl
multiplex
diagnost
workflow
process
